 |
|
|
| |
High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2)
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Lawrence Serfaty1; Stephen Pianko2; Ziv Ben Ari3; Alex L. Laursen4; Jesper Hansen5; Hsueh-Cheng Huang6; Shu Jin6; Jennifer Bourque6; Hong Liu6; Anjana Grandhi6; Mandy Su6; Noel Gendrano6; Doreen Fernsler6; Frank Dutko6; Bach-Yen T. Nguyen6; Janice Wahl6; Eliav Barr6; Wendy W. Yeh6; Rebeca Plank6; Joan R. Butterton6; Edward J. Gane7
1Saint-Antoine Hospital, Paris, France; 2Monash Health, Clayton, VIC, Australia; 3Sheba Medical Center, Tel Hashomer, Israel; 4Aarhus University Hospital, Skejby, Aarhus N, Denmark; 5Aalborg University Hospital, Aalborg, Denmark; 6Merck & Co., Inc., Kenilworth, NJ, USA; 6Auckland Clinical Studies, Auckland, New Zealand
EASL:Safety and Efficacy of the Fixed-dose Combination Regimen of Uprifosbuvir (MK-3682) / Grazoprevir / Ruzasvir in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection Who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) - (04/24/17)
EASL: Elbasvir/Grazoprevir Plus Sofosbuvir ± Ribavirin in Treatment-Naive And Treatment-Experienced People With Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: SVR24 Results of the C-ISLE Study - (04/21/17)
EASL: Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck's ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C - (04/24/17)
EASL: Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-world experience from the TRIO Network - (04/26/17)
EASL: Real-world use of elbasvir/grazoprevir and outcomes in patients with Chronic Hepatitis C: Retrospective data analyses from the TRIO Network. - (04/26/17)
|
| |
|
|
|
|
|
